NextCure, Inc.
NXTC
$0.3901
-$0.0069-1.74%
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
--
Headlines
4/4/2025
-
GuruFocus
4/4/2025
-
Globe Newswire
3/20/2025
-
Ticker Report
3/17/2025
-
TipRanks Financial Blog
3/17/2025
-
The Fly
3/8/2025
-
Ticker Report
3/8/2025
-
TipRanks Financial Blog
3/8/2025
-
TipRanks Financial Blog
3/6/2025
-
GuruFocus
3/6/2025
-
Globe Newswire
1/14/2025
-
Ticker Report
1/10/2025
-
GuruFocus
1/10/2025
-
The Fly
1/10/2025
-
Globe Newswire
12/10/2024
-
GuruFocus
12/10/2024
-
The Fly
12/10/2024
-
Globe Newswire
11/26/2024
-
GuruFocus
11/26/2024
-
Globe Newswire
11/19/2024
-
The Fly
11/19/2024
-
Globe Newswire
11/15/2024
-
GuruFocus
11/14/2024
-
GuruFocus
11/13/2024
-
Simply Wall St
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, March 6, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Beginning of May (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
240 399 4900
Address
9000 Virginia Manor Road
Beltsville, MD 20705
Beltsville, MD 20705
Country
Year Founded
Business Description
Sector
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It...
more
